Search
Close this search box.
×
Search
[custom_company_search_form]
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,138.16
0.38%
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,138.16
0.38%
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,138.16
0.38%
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,138.16
0.38%
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,138.16
0.38%
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,138.16
0.38%
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,138.16
0.38%
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,138.16
0.38%
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,138.16
0.38%
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,138.16
0.38%
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)

Stock Piper AI Index

Stock Piper AI Index

Subscribe
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,138.16
0.38%
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,138.16
0.38%
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,138.16
0.38%
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,138.16
0.38%
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,138.16
0.38%
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,138.16
0.38%
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,138.16
0.38%
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,138.16
0.38%
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,138.16
0.38%
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)
Lithium
44.97
0.87%
Gold
2,709.90
0.83%
Copper
4.07
(0.07%)
Oil
71.24
1.51%
Bitcoin
98,138.16
0.38%
FTSE 100
8,262.10
1.38%
Nikkei 225
38,283.85
0.36%
Dow Jones
44,296.51
0.97%
Iron Ore
100.20
(1.77%)
USD/AUD
0.65
0%
Hang Seng
19,229.97
(1.96%)

Nyrada Inc

NYR

ASX

Nyrada Inc (NYR) is a drug discovery and development company, specialising in novel small-molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol-lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke.

Latest Posts

Line Chart with Gradient
Price
$0.100
-0.005 (-4.76%)
At Close 22/11 (AEST)
Related Companies
ARGENICA THERAPEUTICS LIMITED
$AGN
STARPHARMA HOLDINGS LIMITED
$SPL
CLARITY PHARMACEUTICALS LTD
$CU6
PERCHERON THERAPEUTICS LIMITED
$PER
FIREBRICK PHARMA LIMITED
$FRE

Leave a Comment on NYR


Comments for NYR

    Latest Posts

    nyrada-inc-asx-nyr-raises-3-36-million-for-drug-development-nyr
    Health Care $NYR
    Nyrada Inc (ASX: $NYR) raises $3.36 million for drug developmentAdvancing clinical trials of NYR-BI03 with newly secured funds and planning for future FDA applications
    October 28, 2024
    nyrada-inc-asx-nyr-requests-trading-halt-for-capital-raising-nyr
    Health Care $NYR
    Nyrada Inc (ASX: $NYR) requests trading halt for capital raisingBiotechnology firm Nyrada Inc announces trading halt pending key capital raising update
    October 24, 2024
    nyrada-asx-nyr-advances-lead-drug-candidate-towards-clinical-trial-nyr
    Health Care $NYR
    Nyrada (ASX: $NYR) advances lead drug candidate towards clinical trialQuarterly report highlights progress in NYR-BI03 development and strategic financial planning
    October 24, 2024
    nyrada-inc-asx-nyr-completes-preclinical-studies-for-nyr-bi03-nyr
    Health Care $NYR
    Nyrada Inc. (ASX: $NYR) completes preclinical studies for NYR-BI03Initial findings show strong efficacy in treating ischemia-reperfusion injury, paving way for clinical trials
    October 23, 2024
    nyrada-inc-asx-nyr-demonstrates-strong-cardioprotection-in-coronary-heart-disease-study-nyr
    Health Care $NYR

    Nyrada Inc (ASX: $NYR) demonstrates strong cardioprotection in coronary heart disease study

    NYR-BI03 shows 86% cardioprotection in preclinical rat study, positioning as novel treatment for myocardial infarction

    October 1, 2024
    nyrada-inc-asx-nyr-requests-trading-halt-for-study-results-announcement-nyr
    Health Care $NYR

    Nyrada Inc (ASX: $NYR) requests trading halt for study results announcement

    Trading halt requested for announcement regarding new indication study results

    October 1, 2024
    nyrada-inc-asx-nyr-pauses-trading-pending-further-announcement-nyr
    Health Care $NYR

    Nyrada Inc (ASX: $NYR) pauses trading pending further announcement

    Trading temporarily halted as company prepares for upcoming news

    October 1, 2024
    nyrada-inc-asx-nyr-completes-dog-toxicology-study-for-lead-brain-injury-drug-nyr-bi03-nyr
    Health Care $NYR

    Nyrada Inc (ASX: $NYR) completes dog toxicology study for lead Brain Injury drug NYR-BI03

    Successful completion of key milestone in Brain Injury program

    September 27, 2024
    nyrada-inc-asx-nyr-progresses-rat-cns-testing-for-nyr-bi03-nyr
    Health Care $NYR

    Nyrada Inc (ASX: $NYR) progresses rat CNS testing for NYR-BI03

    Company continues to report on GLP study results for first in class neuroprotection treatment

    August 6, 2024
    nyrada-inc-asx-nyr-progresses-safety-studies-for-lead-brain-injury-drug-nyr-bi03-nyr
    Health Care $NYR

    Nyrada Inc (ASX: $NYR) progresses safety studies for lead Brain Injury drug NYR-BI03

    NYR-BI03 demonstrates safety and tolerability in GLP studies, Phase I clinical trial on track

    July 16, 2024
    nyrada-inc-asx-nyr-progresses-brain-injury-drug-candidate-nyr-bi03-nyr
    Health Care $NYR

    Nyrada Inc (ASX: $NYR) progresses brain injury drug candidate NYR-BI03

    Reports strong efficacy in preclinical stroke study and commences GLP safety testing studies

    April 10, 2024
    nyrada-asx-nyr-raises-1-755-million-via-placement-nyr
    Health Care $NYR

    Nyrada (ASX: $NYR) raises $1.755 million via placement

    Raises funds for pre-clinical GLP study and Phase I human clinical trial of NYR-BI03

    March 6, 2024
    nyrada-inc-asx-nyr-requests-trading-halt-for-proposed-capital-raising-nyr
    Health Care $NYR

    Nyrada Inc (ASX: $NYR) requests trading halt for proposed capital raising

    Trading halt requested by Nyrada Inc ahead of market announcement

    March 4, 2024

    NYR

    $NYR

    Nyrada Inc (ASX: $NYR) raises $3.36 million for drug development

    Advancing clinical trials of NYR-BI03 with newly secured funds and planning for future FDA applications

    NYR

    $NYR

    Nyrada Inc (ASX: $NYR) requests trading halt for capital raising

    Biotechnology firm Nyrada Inc announces trading halt pending key capital raising update

    NYR

    $NYR

    Nyrada (ASX: $NYR) advances lead drug candidate towards clinical trial

    Quarterly report highlights progress in NYR-BI03 development and strategic financial planning

    NYR

    $NYR

    Nyrada Inc. (ASX: $NYR) completes preclinical studies for NYR-BI03

    Initial findings show strong efficacy in treating ischemia-reperfusion injury, paving way for clinical trials

    NYR

    $NYR

    Nyrada Inc (ASX: $NYR) demonstrates strong cardioprotection in coronary heart disease study

    NYR-BI03 shows 86% cardioprotection in preclinical rat study, positioning as novel treatment for myocardial infarction

    NYR

    $NYR

    Nyrada Inc (ASX: $NYR) requests trading halt for study results announcement

    Trading halt requested for announcement regarding new indication study results

    NYR

    $NYR

    Nyrada Inc (ASX: $NYR) pauses trading pending further announcement

    Trading temporarily halted as company prepares for upcoming news

    NYR

    $NYR

    Nyrada Inc (ASX: $NYR) completes dog toxicology study for lead Brain Injury drug NYR-BI03

    Successful completion of key milestone in Brain Injury program

    NYR

    $NYR

    Nyrada Inc (ASX: $NYR) progresses rat CNS testing for NYR-BI03

    Company continues to report on GLP study results for first in class neuroprotection treatment

    NYR

    $NYR

    Nyrada Inc (ASX: $NYR) progresses safety studies for lead Brain Injury drug NYR-BI03

    NYR-BI03 demonstrates safety and tolerability in GLP studies, Phase I clinical trial on track

    Load More
    No More Posts
    Related Companies
    ALTHEA GROUP HOLDINGS LIMITED
    $AGH
    AMPLIA THERAPEUTICS LIMITED
    $ATX
    ARGENICA THERAPEUTICS LIMITED
    $AGN
    IMMURON LIMITED
    $IMC
    GENETIC SIGNATURES LIMITED
    $GSS

    ASX News, First
    & Fast.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    By clicking Subscribe, you agree to our Terms & Conditions
    © 2024 Stock Piper.
    All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support

    Socials

    Facebook
    Twitter
    LinkedIn
    © 2024 Stock Piper. All rights reserved

    Blog

    Healthcare
    Materials
    Real Estate
    Consumer Staples
    Consumer Discretionary Brief
    Utilities

    Company

    About us
    Terms of use
    Privacy Policy

    Support

    Contact Support
    © 2024 Stock Piper. All rights reserved
    Social Media Auto Publish Powered By : XYZScripts.com
    Stock Piper AI Index
    Subscribe
    Join FREE Newsletter

    Stock Piper AI Index Coming Soon!

    Join our Newsletter to gain exclusive insight and be notified once we are live.

    By clicking Subscribe, you agree to our Terms & Conditions

    ASX News, First And Fast.

    Get all the latest market updates straight to your inbox.

    By clicking Subscribe, you agree to our Terms & Conditions